ID

Description

GeneRatio

BgRatio

pvalue

p.adjust

qvalue

Count

hsa05205

Proteoglycans in cancer

179/5024

204/8018

4.49E−16

1.45E−13

7.81E−14

179

hsa04218

Cellular senescence

141/5024

160/8018

2.95E−13

4.76E−11

2.56E−11

141

hsa04010

MAPK signaling pathway

239/5024

295/8018

2.60E−12

2.79E−10

1.50E−10

239

hsa04550

Signaling pathways regulating pluripotency of stem cells

125/5024

142/8018

8.16E−12

6.59E−10

3.54E−10

125

hsa04390

Hippo signaling pathway

136/5024

157/8018

1.46E−11

8.60E−10

4.62E−10

136

hsa01521

EGFR tyrosine kinase inhibitor resistance

75/5024

79/8018

1.60E−11

8.60E−10

4.62E−10

75

hsa05225

Hepatocellular carcinoma

144/5024

168/8018

2.11E−11

9.75E−10

5.24E−10

144

hsa05131

Shigellosis

194/5024

236/8018

2.58E−11

1.04E−09

5.60E−10

194

hsa05166

Human T-cell leukemia virus 1 infection

181/5024

219/8018

4.89E−11

1.76E−09

9.44E−10

181

hsa05220

Chronic myeloid leukemia

72/5024

76/8018

5.65E−11

1.82E−09

9.81E−10

72

hsa05211

Renal cell carcinoma

66/5024

69/8018

1.02E−10

2.88E−09

1.55E−09

66

hsa04150

mTOR signaling pathway

133/5024

155/8018

1.07E−10

2.88E−09

1.55E−09

133

hsa04110

Cell cycle

109/5024

124/8018

2.25E−10

5.58E−09

3.00E−09

109

hsa04120

Ubiquitin mediated proteolysis

118/5024

136/8018

2.68E−10

6.18E−09

3.32E−09

118

hsa04933

AGE-RAGE signaling pathway in diabetic complications

90/5024

100/8018

4.87E−10

1.00E−08

5.38E−09

90